Old Web
English
Sign In
Acemap
>
authorDetail
>
Suthakar Sabapathy
Suthakar Sabapathy
Eisai
Oncology
Lenvatinib
Hepatocellular carcinoma
Clinical endpoint
cost effectiveness
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
2021
Journal of Clinical Oncology
David Trueman
Yifeng Liu
Marc Geadah
Nicholas Hon
Suthakar Sabapathy
Laveena Kamboj
HuiMin Li
Melanie Lucero
Genevieve Meier
Show All
Source
Cite
Save
Citations (0)
The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
2021
Canadian Journal of Gastroenterology & Hepatology
Brandon M. Meyers
Arndt Vogel
Paul Marotta
Petr Kavan
Laveena Kamboj
Janice Pan
Marc Geadah
David Trueman
Suthakar Sabapathy
Show All
Source
Cite
Save
Citations (0)
1